Psychedelics in Mental Health Research

Psychedelics are emerging as one of the most promising — and complex — frontiers in mental health research. Compounds such as psilocybin, MDMA, and ketamine are being studied for their potential to treat depression, PTSD, anxiety, and other conditions. As interest grows, The STARR Coalition is engaging research sites, sponsors, and advocacy partners to ensure that psychedelic trials are conducted ethically, responsibly, and with community trust at their core.

The STARR Coalition is compiling this information to support education, awareness, and collaboration among research sites and community stakeholders. Individuals and organizations should consult qualified professionals and relevant regulatory authorities before making decisions related to psychedelic research participation or conduct.

This page is intended to be a living document. As new areas and resources are identified, they will be included in this resource page. We welcome any input and suggestions on new areas, resources, and tools to help support and advance clinical research.

Benefits of including psychedelic studies in your portfolio

The psychedelic research space is expanding rapidly, with significant investment, sponsor activity, and public interest driving new clinical programs worldwide. For clinical research sites, this growth represents both a strategic business opportunity and a chance to contribute to one of the most transformative areas in modern mental health care.

1. Participate in a Rapidly Growing Area of Research
Psychedelic trials are among the fastest-growing segments of mental health research, with new sponsors, indications, and compounds entering development each year. Engaging early positions sites to build relationships with key industry leaders, attract new studies, and establish themselves as trusted partners in a field that’s gaining global momentum.

2. Strengthen Sponsor Relationships and Visibility
Sponsors and CROs are actively seeking qualified sites with the infrastructure, experience, and willingness to support psychedelic studies. Sites that demonstrate readiness and community credibility stand out as leaders in an area where capable partners are in high demand.

3. Expand Clinical and Operational Expertise
Psychedelic trials often involve unique protocols that emphasize participant preparation, monitoring, and integration. Participating in these studies builds valuable expertise in holistic participant care, risk management, and complex study design — strengthening a site’s overall capabilities.

Operational and regulatory considerations

Psychedelic trials bring unique operational demands and oversight. Sites that prepare early—with clear SOPs, trained staff, and robust participant-safety systems—are best positioned to execute high-quality studies and attract sponsors.

1) Regulatory posture & oversight

• Evolving status: The regulatory landscape for compounds like psilocybin and MDMA is changing. Assign an owner to track FDA/DEA updates, state rules, and IRB guidance and to trigger rapid SOP updates as needed.

• IRB readiness: Ensure protocols address altered states of consciousness, extended session days, audio/video capture (if used), and structured integration visits. Include re-consent and withdrawal procedures, and plans for emergent psychiatric events.

• IND/GCP compliance: Confirm 1572, training records, delegation logs, and GCP currency. Expect enhanced monitoring and potential DSMB involvement.

• Insurance & liability: Verify your professional liability and site policies explicitly cover psychedelic dosing sessions, extended visit durations, and psychotherapy components.

2) Controlled-substance management (if applicable)

• Licensing & scope: Confirm any DEA/state registrations needed for storage/dispensing; align with your pharmacist of record.

• Secure storage & chain of custody: Double-locked storage, restricted access, temperature monitoring (if required), inventory reconciliation, returns/destruction SOPs, and deviation reporting.

• Drug accountability: Session-day dose prep, witnessing, and documentation must be precise to protect blinding and auditability.

3) Facility & environment (“set and setting”)

• Dedicated dosing rooms: Quiet, private rooms with continuous observation, comfortable furnishings, adjustable lighting/sound; clear privacy signage.

• Medical safety station: Vital-signs monitoring, BLS/ACLS-trained clinician on site, emergency meds/equipment (e.g., oxygen), and transfer agreements with nearby higher-acuity care.

• Session logistics: Dosing days can run 6–8+ hours—plan room turnover, staff breaks, meals, and a post-session safe-transport policy (no patient driving).

4) Staffing, credentials, and training

• Therapist pairs/monitors: Many protocols require two facilitators for dosing days plus a medical lead. Build staffing models (and budgets) around high therapist:participant ratios.

• Training: GCP, protocol-specific therapy manuals, trauma-informed care, de-escalation, drug–drug interaction awareness, and emergency response.

• Supervision & fidelity: Schedule supervision sessions and use fidelity checklists; some studies require audio/video for monitoring adherence (with explicit consent and secure storage).

5) Community & communications

• Stigma-aware outreach: Prepare neutral, science-based messaging for participants, families, and referring clinicians.

• After-session support: Provide clear “what to expect” guides, caregiver instructions (when appropriate), and crisis contacts.

6) Budgeting & contracting

• Session-day economics: Long visits and dual-facilitator models require higher per-visit budgets; include premiums for weekend/evening coverage.

• Training & start-up: Price therapist manual training, simulation drills, and room build-out.

• Ancillaries: Account for transport policies, meals, audio/video secure storage, and higher monitoring frequency.

7) Readiness checklist (quick start)

• Named Regulatory Watch owner and update cadence

• DEA/state requirements verified (if applicable)

• Dosing room configured; emergency gear and ACLS coverage in place

• Therapist pair identified; training & supervision scheduled

• Consent language finalized for altered states & recordings

• Chain-of-custody and accountability SOPs approved

• After-hours on-call pathway and post-session transport policy set

• Budgets reflect extended days and therapy components

• Community communications plan and stigma-sensitive materials ready

Community engagement and stigma reduction

This page provides general information and resources related to psychedelics in clinical research. It is not intended as medical advice, endorsement, or regulatory guidance, nor does it reflect an official position on any specific compound, study, or sponsor.